Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13497261 | 1.00 | ABAT (0.46) | ABATALDH1A1HTTLMNAKDM4E | |
| SCHEMBL13497336 | 1.00 | ABAT (0.46) | ABATALDH1A1HTTLMNAKDM4E | |
| SCHEMBL13497255 | 1.00 | ABAT (0.46) | ABATALDH1A1HTTLMNAKDM4E | |
| SCHEMBL13497349 | 1.00 | ABAT (0.46) | ABATALDH1A1HTTLMNAKDM4E | |
| SCHEMBL1828453 | 1.00 | ABAT (0.46) | ABATALDH1A1HTTLMNAKDM4E | |
| SCHEMBL13497265 | 1.00 | ABAT (0.46) | ABATALDH1A1HTTLMNAKDM4E | |
| SCHEMBL16501524 | 0.87 | TDP1 (0.33) | ABATHTTLMNAKDM4ETDP1 | |
| SCHEMBL16501533 | 0.87 | TDP1 (0.33) | ABATHTTLMNAKDM4ETDP1 | |
| SCHEMBL16501526 | 0.87 | TDP1 (0.33) | ABATHTTLMNAKDM4ETDP1 | |
| SCHEMBL16501522 | 0.87 | TDP1 (0.33) | ABATHTTLMNAKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318383-B1 | PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20110301350-A1 | PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301350-A1 | PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301350-A1 | PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS | CCNB1, CCNB2, CYP1B1 | ABAT 4532/4885ALDH1A1 399/4885HTT 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.